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bebiondi@libero.itAbstractObesity and thyroid diseases are common disorders in the general population and they frequently occur in single individuals.
Alongside a chance association, a direct relationship between ‘thyroid and obesity’ has been hypothesized. Thyroid hormone
is an important determinant of energy expenditure and contributes to appetite regulation, while hormones and cytokines
from the adipose tissue act on the CNS to inform on the quantity of energy stores. A continuous interaction between the
thyroid hormone and regulatory mechanisms localized in adipose tissue and brain is important for human body weight
control and maintenance of optimal energy balance. Whether obesity has a pathogenic role in thyroid disease remains
largely a matter of investigation. This review highlights the complexity in the identification of thyroid hormone deficiency in
obese patients. Regardless of the importance of treating subclinical and overt hypothyroidism, at present there is no
evidence to recommend pharmacological correction of the isolated hyperthyrotropinemia often encountered in obese
patients. While thyroid hormones are not indicated as anti-obesity drugs, preclinical studies suggest that thyromimetic drugs,
by targeting selected receptors, might be useful in the treatment of obesity and dyslipidemia.l E
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mEuropean Journal of
Endocrinology
(2014) 171, R137–R152IntroductionObesity and thyroid diseases are common disorders in the
general population and they frequently occur in single
individuals.
Alongside a chance association, a direct relationship
between ‘thyroid and obesity’ has been hypothesized(1, 2, 3, 4, 5). Thyroid hormone is indeed an important
determinant of energy expenditure and contributes to
appetite regulation. On the other hand, secretory products
from the adipose tissue act on the CNS to inform on the
quantity of energy stores, and this may have an impact onndocrinology
n focused on
es in patients
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axis (1, 2, 5).
An increase in body weight (on average 2.86 kg),
which was reverted by treatment with thyroid hormone,
was historically described in myxedematous patients (6).
Yet, it was promptly recognized that a decrease in the fat
free mass accounted for most of the body weight reduction
(7). In line with this effect of thyroid hormones on body
size, weight loss is historically reported among the main
features of thyrotoxicosis (8).
Many attempts have been made to treat obese
euthyroid subjects with thyroid hormones and/or their
analogs in the effort to stimulate energy expenditure,
especially during regimens of dietary restriction (1).
The matter is a complex one, and it is further amplified
by the fact that obese patients may display alterations in
their thyroid function tests, thus raising the question of
whether a specific substitution treatment is advisable.
Epidemiological data suggest that obesity might be
associated with an increased incidence of thyroid cancer.
This association, although still debated, prompted a
discussion on the possible mechanisms underlying the
effect of obesity on thyroid oncogenesis. This review
article aims to analyze relevant data in the literature and
to discuss current opinions on these topics.The thermogenic effect of thyroid hormones
Thyroxine (T4) is the major secretory product of the
thyroid gland and it is a precursor of the active form
of the hormone, the 3,5,3 0-triiodothyronine (T3), which is
mainly produced in peripheral tissues by 5 0-deiodination
of T4 (9). Thyroid hormone production is controlled by
the thyroid-stimulating hormone (TSH) that is secreted by
the anterior pituitary gland. T3 and T4 act directly on the
pituitary and hypothalamus to regulate TSH production
through a classical negative feedback loop (10).
Body weight regulation is achieved through a fine-
tuning between energy intake and energy consumption,
the latter being determined by resting energy expenditure
(REE), non-exercise activity, and voluntary physical
activity. In homeothermic species, such as humans, T3
has acquired a critical role in temperature homeostasis and
is responsible for w30% of REE (11). The T3-induced
thermogenic activity is exerted through the thyroid
hormone receptor a (TRa) (12, 13), while TRb is a key
regulator of cholesterol metabolism (14). Mice lacking all
TRs display a phenotype characterized by decreased basal
metabolic rate, decreased body temperature, and cold
intolerance (15). Besides its influence on thermogenesis,www.eje-online.orgT3 might also influence REE by regulating the spontaneous
motor activity. Indeed, shortly after the injection of T3
into the pre-optic region of hypothyroid rats, an increase
in motor activity is observed (16).
Through an interaction with adipose tissue, the
hypothalamic–pituitary–thyroid axis mediates the
adaptations of both metabolism and thermogenesis by
regulating: i) transcription factors involved in adipogenesis
of white adipose tissue (WAT) and brown adipose tissue
(BAT); ii) genes involved in lipid metabolism (lipogenesis
and lipolysis) and oxidation; and iii) genes regulating
thermogenesis in BAT (17). The TR isoforms a1, a2, and
b1 are expressed in WAT and BAT. In WAT, T3 affects
the lipolytic activity (18), which is mediated by a
cAMP-dependent mechanism and is synergized by the
adrenergic system. Thermogenesis is also regulated by
thyroid hormone at the hypothalamic level. The TR is
expressed in the hypothalamus and modulates the
sympathetic nervous output to BAT (19). This contributes
to the negative energy balance occurring in the
thyrotoxic status.
During cold exposure, the thyroid hormone-
activating enzyme type 2 deiodinase (D2) increases the
generation of T3 in BAT, thus promoting heat production
(20). This is the core pathway of the so-called adaptive or
facultative nonshivering thermogenesis. The thermogenic
effect of T3 in BAT is mediated by the uncoupling
protein 1 (UCP1) and possibly by the UCP3 via a proton
leak through the inner membrane of the mitochondria.
Additional mechanisms, such as increased turnover of
calcium in the sarcoplasmic reticulum (11), are probably
involved. No changes in BAT activity have been so far
demonstrated in humans related to fasting or overfeeding
(21). The presence of BAT was for a long time considered of
negligible importance in humans. This concept has been
recently revised because BAT activity was found to be
impaired in obese subjects and significantly enhanced by
cold exposure (22, 23, 24). The hypothesis postulating a
relevant role for BAT in facultative thermogenesis and
body weight regulation in humans is intriguing, but needs
further proof. Recently, a new fat lineage named ‘beige’
adipose tissue has been described in rodents (25). Beige
adipocytes were found to be inter-dispersed in WAT. The
gene expression pattern of these cells is intermediate
between white and brown fat (hereof the name). Beige
adipose cells show low UCP1 mRNA levels and can be
transformed into brown adipocytes by cAMP. It is not
known whether T3 has any regulatory role on the activity
of this fat cell lineage. Clarifying this issue would be
important because in humans the previously identified
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Review F Santini and others Thyroid hormone and obesity 171 :4 R139brown fat deposits were recently shown to be mainly
composed by beige adipocytes (25, 26).
The pleiotropic effects of thyroid hormones on
adipogenesis, fat metabolism, and thermogenesis raise
the question of whether a primary dysfunction of the
thyroid might result in a change in adipose mass.Feeding and thyroid hormone
The relationship of serum thyroid hormones with feeding
was elegantly investigated over 30 years ago (27, 28, 29,
30, 31, 32) and most of the conclusions drawn by those
pioneering works can still be considered valid. In lean
subjects, the production rate of T3, but not that of T4,
significantly increases during overfeeding. On the other
hand, a caloric deficit, both in lean and in obese subjects,
is characterized by a reduction in T3 and the concomitant
increase in reverse T3 in the circulation. These effects
appear related both to the caloric content and the
composition of the diet.
The early studies already blamed the unjustified idea
that obesity was related to thyroid dysfunction because of
both the patients’ and the physicians’ desire of ascribing the
increased adiposity to a disease that could exonerate them
from responsibility and allow some form of treatment (32).
Experimental data advocate an important role for
thyroid hormone and deiodinases in the regulation of
feeding. In mammals, the peripheral administration of T3
has a catabolic effect and results in a decrease in body weight.
However, when the thyroid hormone is injected into the
hypothalamus, anabolic actions result, which include an
increased appetite, and may thus favor body weight gain.
In mice, fasting increases glial D2 activity and T3 local
production in the arcuate nucleus (ARC), thus promoting
mitochondrial proliferation and stimulation of NPY/AgRP
orexigenic neurons (33). Furthermore, T3 exerts a negative
feedback on the hypothalamic expression of type 4 melano-
cortin receptor (34), apivotalmediatorof theanorecticeffects
of leptin (35). Changes in the activity of hypothalamic
deiodinase (D2 and D3) and of the local availability of T3
were shown to be major regulators of seasonal changes in
body weight in hibernating mammals (36).The leptin–thyroid relationship
Leptin, an adipocyte-derived hormone, is a long-term
regulator of body weight, acting through inhibition of
food intake and stimulation of both energy expenditure
(37) and locomotor activity (38).Leptin receptors (Lep-Rb) are expressed primarily in
the CNS, but also in peripheral organs such as lung,
pancreas, and hematopoietic and immune cells (39, 40).
Besides the ARC of the hypothalamus, which is considered
the main action site of leptin, Lep-Rb have been found
in the pituitary and on TRH-secreting neurons of the
paraventricular nucleus (PVN) (41). Fasting is charac-
terized by the fall of circulating leptin levels due to a
reduction in fat mass and to a series of neuro-endocrine
adaptations aimed at conserving energy. A down-
regulation of the hypothalamus–pituitary–thyroid axis,
mediated by low leptin levels, might play a role in this
adaptation process.
In murine models of fasting, leptin administration
reverses the reduced hypothalamic expression of TRH and
increases the expression of D2 (42, 43), the effect on
pituitary expression of TSH being less prominent. The
action of leptin on TRH in the PVN occurs directly through
an effect on TRH neurons expressing Lep-R and indirectly
through a-MSH production in POMC neurons of the
ARC-targeting TRH neurons (44).
In lean healthy subjects, the circadian rhythms of
TSH and leptin are superimposable (45), and the
subcutaneous administration of leptin significantly blunts
the fall of TSH secretion induced by prolonged fasting
(46). These findings indicate that leptin has a regulatory
effect on TSH secretion. Accordingly, leptin adminis-
tration at physiological doses can partially reverse the
fall of circulating thyroid hormones, which occurs during
prolonged caloric restriction (47).
Taken together, these data support the view that a
reduction in serum leptin levels acts as a peripheral signal
capable of directly inhibiting the hypothalamus–
pituitary–thyroid axis. This function, being exerted at
the hypothalamic level through an inhibition of TRH
expression and secretion, would be an ancestral one,
aimed at saving energy in conditions of food shortage.
Partial central hypothyroidism was initially reported
in patients with congenital lack of leptin (48), although
this dysfunction was not confirmed in more recently
described cases (49). Congenital lack of leptin does
not affect the correct development of a normal
hypothalamus–pituitary–thyroid axis, and in leptin-
deficient patients it is unclear whether and to what extent
leptin treatment influences thyroid function.
A large number of studies investigated the relation-
ship between thyroid dysfunctions and circulating levels
of leptin, but the reported results were highly conflicting
both in basal conditions and after correction of the
thyroid dysfunction (5, 50, 51). Overall, the evidencewww.eje-online.org
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Review F Santini and others Thyroid hormone and obesity 171 :4 R140supporting a direct action of T4 or T3 on leptin regulation
is modest.
A bidirectional interaction is suggested by the
intriguing observation that TSH receptors are expressed
on adipocytes (52) and that the in vivo administration of
recombinant human TSH at supra-physiological doses can
induce the release of small but significant amounts of leptin
which are proportional to the adipose mass (53). The latter
finding confirms that functioning TSH receptors are
expressed on the surface of white adipocytes. The physio-
logic and pathologic roles played by activation of TSH
receptor in white adipocytes remain a matter of investi-
gation. The possibility was also investigated that TSH, by
binding to its receptor on brown adipocytes, may stimulate
thermogenesis, thus preventing an excessive drop in body
temperature in hypothyroidism (54, 55, 56, 57).Thyroid function and structure in
obese subjects
Thyroid function has been extensively investigated in
obese subjects with the purpose of relating the increase
in body weight with an underlying thyroid disturbance.
A recent review of 29 studies assessed the relationship
between serum TSH and BMI in euthyroid subjects (58).
Eighteen of these studies showed a positive correlation
between the measures of adiposity and serum TSH. So far,
these results have been confirmed in all available
longitudinal studies. Data regarding the circulating
concentrations of thyroid hormones are less univocal
because the serum levels of FT3 were reported as increased,
unchanged, or decreased. On the other hand, most studies
reported a general trend toward low/normal levels of FT4
in obese subjects (59, 60, 61, 62, 63, 64, 65, 66). Lately, the
relation between adiposity and serum TSH, FT3, and FT4
was evaluated in a large, representative sample of the adult
population from the National Health and Nutrition
Examination Survey 2007–2008 (67). A significant positive
association of serum TSH and, to a lesser degree, FT3 was
observed with both BMI and waist circumference, while
no association with FT4 could be demonstrated. The
discrepant results obtained in the above reported studies
can be attributed to the inclusion of patients with different
degrees of obesity (i.e. patients with lower degrees of
overweight and those with morbid obesity). Clinical and
genetic evidence support the concept that obesity does
not represent a continuous entity and that morbid obese
patients are likely to harbor a different disease compared
with subjects with milder forms of overweight (64).
Examination of patients at different caloric intakes, eitherwww.eje-online.orgwhile overeating or when on a hypocaloric diet, could also
account for the discrepant results (1). The distribution of
body fat, either subcutaneous or visceral, and insulin
sensitivity were rarely taken into account. Age, sex,
smoking, iodine intake, and definition of the upper-limit
of serum TSH are additional confounders, which might
modify the relationship between BMI and serum TSH.
A recent meta-analysis confirmed that a high-normal
serum TSH is associated with a high BMI (68). However,
the design of analyzed studies does not allow clarifying
whether the high-normal serum TSH is the consequence
or the cause of overweight. This is a critical issue because
in the latter case small variations in serum TSH levels, even
within the normal reference range, might have negative
consequences on body weight and eventually on meta-
bolic and cardiovascular outcomes (69).
As a matter of fact the causes responsible for the
increased serum levels of TSH in obese patients is still
debated. The observation that the serum levels of TSH
normalize after weight loss, resulting either from hypo-
caloric diet or from bariatric surgery (70, 71, 72), suggests
that in obese patients the increased TSH is an adaptive
response of the hypothalamus–pituitary–thyroid axis to
weight gain. If the increase in TSH levels was the primary
event of this response, an increase in serum thyroid
hormones would also be expected. This is in contrast with
most studies, showing low/normal levels of FT4 in obese
subjects. As an alternative explanation, it should be
considered that the turnover rate of T4 is proportional to
body size (73) that is indeed a main determinant of the
substitution dose of levothyroxine (L-T4) in hypothyroid
subjects (74, 75). Thus, an increased rate of thyroid
hormone disposal (resulting from a large body size)
would be the causative event promoting an activation of
the hypothalamus–pituitary–thyroid axis aimed at main-
taining serum thyroid hormones within the euthyroid
range. Eventually, this sequence of events would result in a
low-normal serum FT4 associated with a slightly increased
TSH level and a moderately enlarged thyroid gland. In this
scenario, the serum levels of FT3 would be mainly related
to the ongoing nutritional status (Fig. 1).
The possibility that chronic autoimmune thyroiditis
could be the cause of the increased serum levels of TSH
observed in obese patients has been evaluated in two
recent studies. It was found that autoimmune hypo-
thyroidism is more prevalent in patients with minor
degrees of weight excess (66), whereas slightly increased
serum levels of TSH, being unrelated to thyroid auto-
immunity, predominate in morbidly obese patients (64).
In morbid obese subjects, the serum concentration of
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Figure 1
Tentative representation of the adaptive mechanisms leading to
changes in serum thyroid hormones and TSH in obese subjects.
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Role of thyroid hormone in thermogenesis and the inter-
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Review F Santini and others Thyroid hormone and obesity 171 :4 R141cholesterol was lower than in lean controls having similar
degrees of serum TSH elevation (76). This finding suggests
that the higher serum TSH of morbid obese patients is
not associated with peripheral hypothyroidism.
Although data regarding changes in thyroid structure in
obese patients are scanty, the gland volume, as assessed by
ultrasound (US), was found to be larger in obese compared
with non-obese subjects. This difference was related to the
amount of lean body mass rather than to body weight by
itself (59). After weight loss, a reduction in thyroid volume
was also observed (60). Studies on children and adults also
demonstrated that obesity is associated with a thyroid
hypo-echogenic pattern at US, which occurs independently
from thyroid autoimmunity (77, 78). Indeed, among all
patientswitha thyroidhypo-echogenicpatternof thegland,
only a minority of those with morbid obesity (20%) had
serological evidence of thyroid autoimmunity (78). This
figure was in contrast with the much greater prevalence
(O80%) of thyroid antibodies in non-obese patients. Thus,
thyroid US, a well-established tool for diagnosing thyroid
autoimmune diseases (79), has a poor diagnostic accuracy
in patients with morbid obesity.connections with the brown adipose tissue and the adrenergic
system during hyperthyroidism. [, Increased; Y, decreased;
D2, type 2 iodothyronine deiodinase; SNS, sympathetic nervous
system; b-r, adrenergic b receptor; TR, thyroid hormone
receptor; NE, norepinephrine; UCP1, uncoupling protein 1.Hyperthyroidism and body weight
Despite increased appetite, hyperthyroidism is usually
associated with a variable decrease in body weight, due toa decline in both lean and fat mass, associated with an
increase in total energy expenditure (Fig. 2) (19, 80, 81, 82,
83, 84). The latter phenomenon results from a reduced
thermodynamic efficiency of the biologic machine with
increased heat production (85). As a consequence,
accelerated protein catabolism and skeletal muscle
atrophy has been observed in experimental thyrotoxicosis
(86). Furthermore, hyperthyroidism causes a negative
calcium balance and reduced bone mineral density (87).
The extent of these phenomena depends on the severity
of the thyrotoxic state and the length of exposure.
Occasionally, a paradoxical weight gain is observed in
some thyrotoxic patients because, due to a greatly
increased appetite, their caloric intake exceeds the
augmented energy expenditure. Recovery of body weight
is considered an early-positive response to the
administration of anti-thyroid drugs. With time, the
correction of hyperthyroidism may be responsible for
excessive weight gain, independent of the treatment
modality of thyrotoxicosis: surgery, radioiodine, or
anti-thyroid drugs (88, 89, 90, 91, 92, 93).
The mechanisms responsible for excessive body
weight gain after treatment of hyperthyroidism may
include sub-optimal correction of hypothyroidism,www.eje-online.org
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Review F Santini and others Thyroid hormone and obesity 171 :4 R142reduced energy expenditure due to incomplete recovery of
the muscle mass, and/or greater energy intake than that
required to maintain the individual’s premorbid body
weight. Recently, no change in body weight and resting
energy metabolism has been observed in Graves’ patients
after the cessation of the block and replace therapy
(i.e. anti-thyroid drugs plus L-T4) (94).
This treatment modality, although not generally
recommended by the American Thyroid Association
(95), may be employed when a satisfactory control of
hyperthyroidism is not achieved by the administration of
thionamides alone. Indeed, in Graves’ disease, high levels
of TSH receptor-stimulating antibody are often associated
with a high T3/T4 ratio and large goiters (96, 97).
Administration of thionamides to these patients may be
followed by a reduction in serum T4 to the hypothyroid
range, while serum T3 remains elevated and TSH is
undetectable. In these cases, the block and replace therapy
allow the maintenance of serum thyroid hormones within
the normal range, thus preventing a persistent hypermeta-
bolic state that could eventually exert a detrimental effect
on body weight.Hypothyroidism and body weight
In humans, overt hypothyroidism is associated with
variable degrees of weight gain. While being a frequent
complaint (weight excess was reported in 54% patients
with overt hypothyroidism) (98), weight gain is usually of
limited extent (99). In line with this concept, the BMI was
not found to be greater in elderly women with subclinical
hypothyroidism compared with euthyroid controls (100).
The alterations in body weight associated with
hypothyroidism may reflect both the accumulation of
body fat (83, 101), due to decreased REE and reduced
physical activity, and the increased water content of the
body (102), consequent to a reduced capacity of excreting
free water (103). Hypothyroid subjects also have increased
amounts of glycosaminoglycans that are responsible for
the greater water-binding capacity, a condition that results
in the typical ‘myxedema’ of hypothyroidism (102).
Restoration of euthyroidism is followed by an increase
in REE and even small variations in serum TSH, induced by
L-T4 substitution, are associated with opposite changes in
REE (104, 105). However, in spite of adequate substitution
with L-T4, hypothyroid patients may experience only a
modest and/or transient loss of weight during hormone
treatment (81, 106). Excretion of excess body water, rather
than reduction in fat mass, accounts for this change of
body weight.www.eje-online.orgThere is general agreement that an ideal body weight
should be employed to calculate the final amount of
hormone to be administered to hypothyroid patients.
A study using dual-energy x-ray absorptiometry (DEXA) to
assess body composition in normal-weight, overweight,
and obese subjects provided evidence that lean body mass is
the best predictor of the daily requirements for L-T4 in
hypothyroid patients (74). In that study, the age- and
gender-related differences in the L-T4 substitution dose
reflected the different proportions of lean mass over the
total body weight. Indeed, most metabolic processes of
thyroid hormones, including type 3 inner-ring deiodina-
tion in skin (107), type 2 outer-ring deiodination in skeletal
muscle (108), type 1 outer-ring deiodination, sulfation, and
glucuroconjugation in liver (109), occur within the lean
body compartment. No association was observed between
L-T4 requirement and serum leptin (74), suggesting that the
mass of adipose tissue has a minor impact on L-T4 needs in
hypothyroid subjects.Obesity and thyroid autoimmunity
Susceptibility to autoimmune thyroid disease depends
primarily on genetic determinants, both within the HLA
and non-HLA loci (CTLA4, CD40, PTPN22, TG, and TSH-R
genes), which may be influenced by diverse environmental
stressors, such as iodine intake, chemical pollutants, stress,
drugs, and infectious diseases (110). A causal link between
obesity and thyroid autoimmunity has not been estab-
lished so far, yet observational data from the general
population suggest that obesity may increase the risk of
developing allergies and several autoimmune diseases
(111, 112), possibly through the chronic pro-inflammatory
status resulting from the accumulation of WAT in the obese
patients. In obesity, the immunological tolerance can be
affected both directly and indirectly, via an altered
secretion of adipokines (predominantly leptin, adiponec-
tin, and visfatin) and/or cytokines (interleukin 6 (IL6),
tumor necrosis factor alpha, and interleukin 10 (IL10)). The
final result would be a shift from Th2 to Th1 immune
response; the latter being more prone to produce auto-
immune reactions (112, 113, 114). The visceral adipose
tissue (VAT) contains resident macrophages, endothelial
cells, and T cells with biased T cell receptors, which may
contribute to mount an immune response by producing
excessive amounts of pro-inflammatory cytokines (115).
Moreover, VAT is a reservoir of regulatory T (Treg) cells, a
small subset (5–15%) of the T cell compartment capable of
controlling autoimmune reactions. In vitro, Treg cells have
been shown to be influenced by leptin, which acts by
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Review F Santini and others Thyroid hormone and obesity 171 :4 R143downregulating the proliferation of CD4CCD25C cells,
a Treg subpopulation involved in the control of auto-
immunity (116) and of thyroid cell apoptosis (117).
Experimentally, the immune actions of leptin have been
shown in several autoimmune rheumatic diseases (118).
A clear clinical association between obesity and
autoimmune thyroid diseases is not established to date,
and available studies assessing conventional markers of
thyroid autoimmunity, such as thyroid peroxidase
antibodies (TPOAb) and/or thyroid hypo-echogenicity,
have provided discrepant results due to inherent issues of
accuracy in the context of obesity.
Studies on pediatric populations suggest that obesity
per se is associated with moderately elevated TSH levels in
association with normal or slightly elevated FT4 and/or
FT3 levels (119). Overall, this hormonal profile is observed
in 7–23% of obese children (120). Similar data, indicating
a higher prevalence of elevated serum TSH, were found
both in European and North American populations when
obese children were compared with normal-weight
controls. These higher TSH levels were not related to
autoimmune thyroiditis, iodine deficiency, or signs and
symptoms of hypothyroidism (121, 122). Whether the
raised serum levels of TSH in childhood obesity are an
adaptive phenomenon, aimed at increasing the metabolic
rate in the attempt to prevent further weight gain, or
indicate subclinical hypothyroidism, or may be thyroid
hormone resistance, is still debated. Although the first
hypothesis is strongly supported by the observation that
the serum levels of TSH normalize after substantial weight
loss, an overall consensus has still to be reached. Other
studies reported an increased prevalence of humoral signs
of thyroid autoimmunity in childhood obesity. Radetti
et al. (77) found high levels of TPOAb in nearly 24% of
overweight or obese children. This prevalence is similar to
that observed in children with type 1 diabetes mellitus
(21.6%) (123) and outnumbers current epidemiologic data
in iodine-sufficient schoolchildren, which indicate a
TPOAb prevalence in the range of 3.4–4.6%(124, 125).
Moving to adults, in a large series of obese individuals
referred for bariatric surgery, the prevalence of auto-
immune thyroiditis was 17.1% and that of autoimmune
hypothyroidism 12.3% (126). These prevalence rates are
higher than those reported in the National Health and
Nutrition Examination Survey (NHANES III), which was
performed in an iodine-sufficient population (127). While
data on body weight were not incorporated in NHANES III,
the prevalence rate of positive TPOAb was 11.3%, the
thyroid autoantibody being more prevalent in women and
white people, and significantly associated with hypo- orhyperthyroidism. In the study by Marzullo et al. (66),
which included patients younger than 50 years with
moderate or severe obesity (grades II and III), a twofold
greater prevalence of TPOAb (17%) was found compared
with control subjects (7.6%, P!0.01). In order to explain
the greater prevalence of TPOAb in obese individuals,
an increased presentation of thyroid antigens to the
immune system, possibly resulting from TSH stimulation
of thyroid cells, was postulated, albeit not proven (121).
At variance with these findings, in the study by Rotondi
et al. (64), which was restricted to morbid obesity
(grade III), patients with increased serum levels of TSH
had a low prevalence of TPOAb and did not display the
high female-to-male ratio that is typical of thyroid
autoimmunity. Thus, the prevalence of autoimmune
hypothyroidism was found to be low in this group of
patients with morbid obesity. Based on the latter study,
the likelihood that chronic autoimmune thyroiditis is
the underlying cause of the mild TSH elevation observed
in obese patients remains questionable.
Several limitations apply to currently available studies,
such as a restricted number of population samples, biases
in the selection of patients and controls, and differences
in the study design. The imprecision deriving from the
variability of commercially available assays for TPOAb
should also be considered (128). Such limitations must
be taken into account when considering the prevalence
rate of TPOAb in the general and in the obese population
(64, 66, 129, 130, 131, 132, 133, 134, 135, 136, 137).
As a matter of fact, the question of whether obesity
prompts the development of autoimmune thyroid
diseases remains unanswered and will require future
large comparative studies. Yet, the possible association
between obesity and thyroid autoimmunity remains an
issue of concern because affected individuals would be at
high risk of developing symptomatic hypothyroidism,
which in turn would promote further weight gain or
would hamper weight loss programs. In this regard, we
would like to stress that the clinical meaning of the
moderately raised serum TSH frequently observed in obese
patients differs depending on its underlying cause. If ‘true’
hypothyroidism, as assessed by a concomitant diagnosis
of chronic autoimmune thyroiditis is present, the adverse
consequences will not differ from those of subclinical
hypothyroidism occurring in normal-weight subjects
(138, 139, 140, 141). On the other hand, when no primary
cause of hypothyroidism is found and the alteration of
serum TSH is probably due to obesity itself, the
repercussions of this isolated hyperthyrotropinemia are
not easily envisaged.www.eje-online.org
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Large prospective studies have shown a significant
association of obesity with several types of cancer.
The International Agency for Research on Cancer
classified the evidence for a causal link as ‘sufficient’ for
cancers of the colon, female breast (postmenopausal),
endometrium, kidney, and esophagus. These assump-
tions, together with the worldwide rising trend in obesity,
suggest that overeating might be the most common
avoidable cause of cancer in nonsmokers (142).
The incidence of differentiated thyroid cancer (DTC)
in the North American population nearly tripled in the last
decades, with the most rapid period of increase being
recorded between 1997 and 2006 (143). In the same
timeframe, the prevalence of obesity doubled among adults
in North America and tripled in children and adolescents
(144). The question of whether the epidemics of obesity
might be responsible for the increased incidence rate of
DTC is thus an open matter of debate. A systematic review
of prospective observational studies showed a positive
association between BMI categories at diagnosis and the
risk of developing DTC (HRZ1.18 (95% CI, 1.03–1.35) for
a 5 kg/m2 increase) in both sexes and young adults (age
range, 18–20 years) (145). More recently, a cross-sectional
study has demonstrated that BMI is a significant predictor
of DTC in women (OR, 1.63; 95% CI, 1.24–2.10) but
not in men (OR, 1.16; 95% CI, 0.85–1.57) (146). Thus, it is
conceivable to speculate that obesity might predispose to
DTC, at least in females.
The mechanisms underlying this hypothetical associ-
ation remain largely unclear, but the increased serum level
of TSH, frequently observed in obese patients, might play a
role. Indeed, TSH is a growth factor for thyroid cells and a
predictor of malignancy in thyroid nodules (147, 148).
As such, a recent meta-analysis showed that, in patients
with nodular disease, higher concentrations of TSH, even
within the normal range, are associated with higher odds
of thyroid cancer (149). A potential role for insulin,
insulin-like growth factor (IGF), growth hormone (GH)
secretagogues, and adipokines was also postulated. The
insulin–cancer hypothesis postulates that hyperinsuline-
mia, a common finding in obesity, would decrease the
concentrations of IGF-binding protein 1 (IGFBP1) and
IGFBP2, which, in turn, would increase the bioavailable
free IGF1 levels (150). IGFI has mitogenic and
anti-apoptotic effects, thus it might generically favor
tumor formation and progression. An overexpression of
the insulin receptor A (IR-A) may also contribute to the
activation of the IGF system, at least in poorly DTCs.www.eje-online.orgThis effect would be mediated by the activation of an
autocrine loop involving IGF2 and a paracrine loop
involving IGF1 via the formation of IR/IGF1R hybrids (151).
In addition, an imbalance between estrogens (E2) and
androgens, due to the action of aromatase in the adipose
tissue, could contribute to thyroid carcinogenesis in obese
patients, being responsible for different actions according
to gender and age (152). In thyroid cancer cells, the
biological effects of E2 are mediated by estrogen receptors
a (ERa (ESR1)) in an ERK1/2-related pathway (153).
Further potential links between obesity and DTC
might be ghrelin, the GH-secretagogue receptor, and
obestatin, which are expressed in cancer tissues (154).
Although in vitro studies showed that ghrelin plays a role
in several processes related to cancer progression,
its effects largely vary across different cell types (155).
In particular, a significant decrease in the proliferation of
cell lines of human papillary carcinoma (N-PAP) was
observed after in vitro treatment with ghrelin at concen-
trations ranging from 100 nM to 1 mM (156). At variance
with these data, a study in patients with papillary thyroid
cancer found that the malignancy was associated with
low circulating levels of ghrelin, a condition which is
typically observed in obese individuals (155). These
apparently discrepant in vitro and in vivo findings might
be reconciliated by hypothesizing that low levels of
ghrelin would favor thyroid cell proliferation whilst
supra-physiological doses would have an inhibitory effect.
The obesity-related adipocytokine network might also
play a role in the development of thyroid cancer. Several
in vitro studies investigated the effect of leptin on thyroid
cancer cells, but the results were not univocal. All
investigated thyroid cancer cell lines (the anaplastic
ARO, the follicular WRO, and the papillary CGTH-W3
cell lines) were found to express long-form leptin
receptors. Leptin was shown to promote cell migration
in PTC cells, while inhibiting the migration of follicular
and anaplastic thyroid cancer cells (157). Other in vitro
studies demonstrated that leptin stimulates a more
aggressive PTC phenotype by putative activation of the
PI3K/AKT pathway (158), and also promotes the
de-differentiation of thyroid tumor cells via the JAK2/
STAT3 signaling pathway (159). The possibility that these
effects might result in distinct tumor presentations and
disease courses remains purely theoretical.
Abnormal micro-environment conditions such as
hypoxia (through HIF1a overexpression), chronic inflam-
mation (through NF-kB activation and upregulation of
pro-inflammatory genes), and oxidative stress (due to
the presence of reactive oxygen species) are typically
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development of DTC and, in particular, a subgroup of
cancers characterized by resistance to both 131I treatment
and chemotherapy (160).
The possible association of obesity with autoimmune
thyroid diseases might also play a role because of the
reported association between chronic autoimmune
thyroiditis and thyroid cancer (161).
In conclusion, epidemiologic and experimental data
suggest that obesity might be a risk factor for DTC.
However, this is still a matter of debate deserving
specifically designed clinical and epidemiologic studies
to be clarified.Thyroid hormone as a potential
treatment for obesity
Weight loss up to 5–10% of the initial weight reduces the
risk factors of cardiovascular disease, prevents the
development of type 2 diabetes, and improves other
health outcomes in obese patients. Unfortunately, bar-
iatric surgery is at present the only effective method to
rapidly induce weight loss in morbid obese patients (162).
For decades thyroid hormone preparations have been
inappropriately added to dietary supplements with
potential dangerous effects. The rationale for using thyroid
hormones stems from the common experience that weight
loss induced by a hypocaloric diet frequently fades over
time, and among the possible causes for failure is the
reduced metabolic rate resulting from a decrease in serum
FT3 levels during a low-calorie diet (163). These changes of
thyroid hormone metabolism are regarded as an adaptive
process aimed at minimizing the waste of body protein. The
administration of thyroid hormones (either T3 and/or T4) to
euthyroid obese patients during a hypocaloric diet has been
investigated for decades for its ability to enhance weight
loss (164). Some studies also tried to establish the optimal
dose of thyroid hormones that, while favoring weight loss,
would prevent muscle wasting and adverse cardiac effects
due to subclinical thyrotoxicosis (165, 166, 167). In 2009,
a meta-analysis of the literature by Kaptein et al. (168)
estimated the effectiveness and the risks of T3 and/or T4
therapy in obese patients. Weight loss, protein wasting, and
cardiac function were evaluated. The review included
randomized controlled trials and prospective observational
studies evaluating the effects of T3 and/or T4 treatment in
euthyroid adult obese subjects undergoing caloric depri-
vation. The results of this meta-analysis indicated no
consistent increase in total weight loss during T3 or T4
therapy. A significant weight loss was only observed in 20%of the studies employing T3 treatment. The effects of T3 or
T4 on total weight loss did not correlate with the hormone
dose, the length of treatment, and the duration of caloric
deprivation. The effect of T3 on protein loss, as assessed by
urinary 3-methylhistidine excretion and urinary nitrogen
excretion, did not reach the level of statistical significance
mainly due to the small sample size. However, even
apparently physiologic doses of T3 were able to significantly
reduce the serum levels of TSH (in 50% of the studies).
These data indicate the development of subclinical
thyrotoxicosis. In two studies, the administration of
pharmacologic doses of T3 significantly increased urinary
nitrogen excretion compared with caloric deprivation
alone (169, 170). In a study specifically designed to evaluate
the components of weight loss, 74% of extra weight loss in
the T3 treated group was accounted for by loss of fat free
tissue (171).
Despite the effect of T3 on heat generation, the
hypothesis that T3 administration might lead to a negative
energy balance and to a consequent reduction of lipid
storage is questionable for several reasons. The greater REE
produced by T3 administration can be counterbalanced by
a simultaneous stimulation of appetite, which in turn
results in increased energy intake. Moreover, the increased
lipolysis induced by T3 is associated with the induction
of lipogenesis.Thyroid hormone mimetics as a future tool
for the treatment of obesity and related
co-morbidities?
The development of drugs selectively targeting the different
isoforms of thyroid hormone receptor (TR) represents
an emerging therapeutic tool aimed at improving weight
loss, glucose tolerance, and dyslipidemia and at preventing
atherosclerosis (Table 1) (172). The selective activation
of different TR-mediated pathways is a promising
strategy for treating lipid disorders and obesity (172, 173,
174, 175, 176). Indeed, studies on animals suggested that
thyro-mimetics might be useful in the treatment of obesity,
hepatic steatosis, and atherosclerosis (177).
In humans, many years ago, dextrothyroxine was
used for the treatment of dyslipidemia (178). Despite the
reduction in serum cholesterol levels, dextrothyroxine
increased the overall mortality, due to a contamination of
the drug preparation with the L-enantiomer.
Triiodothyroacetic acid (Triac) has a 3.5-fold higher
affinity for TRb and a 1.5-fold higher affinity for TRa
compared with T3 (179). A study by Ladenson et al. showed
that although Triac improved the lipid pattern inwww.eje-online.org
AUTHOR COPY ONLY
Table 1 Potential use of thyroid hormone analogs in humans.
Compound
TR isoform
specificity bOa Structure Favorable effects Potential indications Side effects
Eprotirome
(KB 2115)
C Y LDL cholesterol High cholesterol Mild elevation in liver enzyme
Y LPA Y Serum T4 chondrocite loss
(phase II discontinued)Y TGs
DTPA
3,5 diiodo-acid
C/K [ CI Obesity [ Marker of bone degradation
Y SVR Heart failure Y T4, Y T3, and Y TSH
Y Cholesterol Statin synergy
Y LPA
Y TGs
Sobetirome GC-1 CC Y Fat mass Obesity Not reported
Y LDL cholesterol NAFLD
Y LPA FH
Y TGs
Tiratricol TRIAC CC Y LDL cholesterol Isolated pituitary
resistance to
thyroid hormones
[ Bone resorption and
turnover
Symptoms of thyrotoxicosis
Y T4 and Y TSH
CI, cardiac index; SVR, systemic vascular resistance; LPA, apolipotrotein (a); TGs, triglycerides; NAFLD, nonalcoholic fatty liver disease; FH, familial
hypercholesterolemia.
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Review F Santini and others Thyroid hormone and obesity 171 :4 R146hypothyroid athyreotic patients, its use was associated
with a negative effect on bone turnover (179).
Sobetirome (GC1), a THRb-selective agonist, is able to
bind TRb with an affinity similar to T3, but has a tenfold
lower affinity for the TRa isoform (180). In the study by
Chiellini et al., sobetirome decreased fat mass by 20% and
improved the lipid profile without increasing food intake
and affecting heart rate or bone mass (180). Treatment of
rats with 3 mg T3/100 g body weight and equimolar
amounts of GC1 (3 mg GC1/100 g body weight) resulted
in a similar loss of fat mass. At variance with T3, which
caused a loss of muscle mass, GC1 had no muscle wasting
effect (181).
In 2010, a randomized, placebo-controlled, double-
blind multicenter trial assessed the efficacy of KB2115
(eprotirome) in lowering the serum levels of LDL
cholesterol. Eprotirome induced a 23–29% reduction in
serum LDL cholesterol, a 22–38% decline in serum
triglyceride, and a 37–45% decrease in lipoprotein(a) in
patients with hypercholesterolemia who were already
receiving simvastatin or atorvastatin, but still had serum
LDL levels above 116 mg/dl (182). The drug had no
adverse effects on the cardiovascular system or on bone
mineral turnover. No significant change in serum TSH or
T3 was reported. Only a slight and transient increase in
liver enzymes was observed. However, body weight did
not change in patients receiving eprotirome.www.eje-online.orgGC24, a second-generation molecule, has a 40-fold
higher affinity for TRb than TRa. In rats, the drug
reduces body fat accumulation, prevents liver steatosis,
improves insulin sensitivity, and normalizes hypertrigly-
ceridemia (183). These favorable actions can be obtained
without significant changes in food intake or untoward
cardiac effects.
In a recent preliminary study, two euthyroid human
volunteers have been treated with 3,5-diiodo-L-thyronine
(184). A significant 4% decrease in body weight was found,
without significant changes in serum FT3, FT4, or TSH.
Unfortunately, changes in fat mass were not evaluated in
this study.
In summary, preclinical studies showed that thyromi-
metic drugs might be useful in treating obesity and
dyslipidemia. The second generation of highly selective
TRb agonists or compounds with additional adipose tissue-
specific effects might be promising in treating obesity.Conclusion
A continuous interaction between the thyroid gland and the
adipose organ is important for human body weight control
and maintenance of optimal energy balance. Thyroid
dysfunctions may affect this equilibrium and always require
proper treatment. Whether obesity has a pathogenic role in
thyroid disease remains largely a matter of investigation.
AUTHOR COPY ONLY
E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Review F Santini and others Thyroid hormone and obesity 171 :4 R147Specifically, this review highlights the complexity in the
identification of thyroid hormone deficiency in obese
patients.Regardless of the importance of treating subclinical
and overt hypothyroidism to improve the cardiovascular
prognosis, at present there is no evidence to recommend a
pharmacological correction of the isolated hyperthyrotro-
pinemia often encountered in obese patients. While thyroid
hormones are not indicated asanti-obesitydrugs, preclinical
studies suggest that thyromimetic drugs, by targeting
selected receptors, might be useful in the treatment of
obesity and dyslipidemia.Declaration of interest
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